Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.37 -0.08 (-1.80%)
price chart
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
One biotech in particular that investors should be watching the cash burn rate of very closely is Arena Pharmaceuticals (NASDAQ: ARNA ) . With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond ...
Related articles »  
Eisai Earnings Give Arena Investors Insights (ARNA)
Additional revenue for Arena can come from manufacturing services, other Eisai collaborative revenue, and the sale of Taigen stock that the company still holds. I anticipate that manufacturing revenue will be between $500,000 and $700,000. I anticipate ...
Stocks Worth Adding To Your Watchlist: Alpha Pro Tech, Ltd. (APT), Arena ...  Markets Emerging
Lorcaserin Data to be Presented at The Obesity Society's Annual ...  MarketWatch
Related articles »  
Arena Offers Tease On Belviq And Phentermine (ARNA)
Arena announced that the 12 week study involving 238 patients met the safety endpoints, but the company stopped short of announcing the results of weight loss, opting to save that data for the Obesity Week Conference next week.
Arena Pharma (ARNA) Gains; Reports Results of Investigational Pilot Study of ...  StreetInsider.com (subscription)
Eisai Announces Top-Line Results of Investigational Study on ...  Japan Corporate News (press release)
Related articles »  
Trader's Buzz: Unilife Corporation (UNIS), Arena Pharmaceuticals (ARNA ...
ARNA shares recently gained $0.01 to $4.36. The stock is down more than 2.22% year-over-year and has lost roughly 24.79% year-to-date.
Pharma Stocks to Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Monday said data from phase 3 clinical trials of its obesity drug BELVIQ (lorcaserin HCl) will be presented at the American College of Clinical Pharmacy meeting taking place through Wednesday of this week.
Related articles »  
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Weekly Performance Is Improving
Arena Pharmaceuticals Inc (NASDAQ:ARNA) has a one year low of $3.26 and a one year high of $7.97. Arena Pharmaceuticals Inc (NASDAQ:ARNA) opened with a price of 4.26 and hit a high of 4.46 with a low of 4.15 on the last trading day.. Arena ...
Watch List -Nanosphere, Inc. (NSPH), Arena Pharmaceuticals, Inc. (NASDAQ ...  Techsonian (press release)
Arena Pharmaceuticals (ARNA) to Release Quarterly Earnings on Monday  WKRB News
Related articles »  
Arena Pharmaceuticals's Market Perform Rating Reiterated at BMO Capital ...
Arena Pharmaceuticals, Inc. logo BMO Capital Markets reiterated their market perform rating on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a research note released on Thursday morning.
Arena Investors Need To Watch Contrave Launch Closely
Arena Pharmaceuticals (NASDAQ:ARNA) investors now have something else to pay attention to. Orexigen ... Eisai may need to at some point, but I expect the company to be conservative and to collect some data before jumping to a rash conclusion.
Arena Pharmaceuticals Receives "Market Perform" Rating from BMO Capital ...
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) traded up 4.46% during mid-day trading on Thursday, hitting $4.45. 4,978,650 shares of the company's stock traded hands. Arena Pharmaceuticals has a one year low of $3.26 and a one year high of $7.97.
News Recap: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Achillion ...  Market News Call
Related articles »  
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA ...
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and ...
Related articles »